PSMD2 mediates the degradation of CYP1A2 and promotes the progression of metabolic dysfunction-associated steatohepatitis

DRUG METABOLISM AND DISPOSITION · Published 2026-07-09 · DOI 10.1016/j.dmd.2026.100363

Authors (8)

Min Liu, Tianhao Liu, Dongsheng Liu, Jiaying He, Qin Shao, Jiye Aa, Guangji Wang, Yuan Xie

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Liu, M., Liu, T., Liu, D., et al. (2026). PSMD2 mediates the degradation of CYP1A2 and promotes the progression of metabolic dysfunction-associated steatohepatitis. DRUG METABOLISM AND DISPOSITION. https://doi.org/10.1016/j.dmd.2026.100363

Related articles

• Virtual special section: Gut microbiota in drug metabolism · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• A 3-step static mechanistic modeling approach to predicting transporter- and enzyme-mediated interaction signals of direct oral anticoagulants · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Investigation of biomarkers for azole antifungal-induced liver injury using primary human hepatocyte spheroids · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Physiologically based pharmacokinetic modeling of the unusual kinetics of ketoconazole due to nonlinear liver binding and metabolism in rats · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Role of CYP3A5 and CYP3A4 in the metabolism and toxicity of 10-hydroxyl mesaconitine, a new potential toxicity marker of Radix Aconiti Lateralis Preparata (Fuzi), in vitro and in vivo · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids—Application to recent real-world cases · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• A comprehensive investigation into the effect of bisphenol A on the expression of drug-metabolizing enzymes: Consequences for endogenous metabolites and xenobiotic pharmacokinetics · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Mechanistic Study on the Species Differences in Metabolism and Excretion Pathways of Ivarmacitinib (SHR0302) between Humans and Rats · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Diagnostic exogenous probe strategy using ezetimibe-glucuronide effectively identifies metabolic dysfunction–associated steatohepatitis · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal
• Absorption, metabolism, and excretion of single dose oral [14C]camizestrant in healthy human female participants · DRUG METABOLISM AND DISPOSITION · 2026 · Same journal